Abstract
The study of the detailed molecular history of cancer development is one of the most promising techniques to understand and fight this diverse and prevalent disease. Unfortunately, this history is as diverse as cancer itself. Therefore, even with next-generation sequencing techniques, it is not easy to distinguish significant (driver) from random (passenger) events. The International Cancer Genome Consortium (ICGC) was formed to solve this fundamental issue by coordinating the sequencing of samples from 50 different cancer types and/or sub-types that are of clinical and societal importance. The contribution of Spain in this consortium has been focused on chronic lymphocytic leukemia (CLL). This approach has unveiled new and unexpected events in the development of CLL. In this review, we introduce the approaches utilized by the consortium for the study of the CLL genome and discuss the recent results and future perspectives of this work.
Similar content being viewed by others
References
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 5:646–674
Stratton MR, Campbell PJ, Futreal PA (2009) The cancer genome. Nature 7239:719–724
Greenman C, Stephens P, Smith R et al (2007) Patterns of somatic mutation in human cancer genomes. Nature 7132:153–158
Bozic I, Antal T, Ohtsuki H et al (2010) Accumulation of driver and passenger mutations during tumor progression. Proc Natl Acad Sci USA 43:18545–18550
Hudson TJ, Anderson W, Artez A et al (2010) International network of cancer genome projects. Nature 7291:993–998
Zhao J, Grant SF (2011) Advances in whole genome sequencing technology. Curr Pharm Biotechnol 2:293–305
Meyerson M, Gabriel S, Getz G (2010) Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet 10:685–696
Ley TJ, Mardis ER, Ding L et al (2008) DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 7218:66–72
Campbell PJ, Stephens PJ, Pleasance ED et al (2008) Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat Genet 6:722–729
Chapman MA, Lawrence MS, Keats JJ et al (2011) Initial genome sequencing and analysis of multiple myeloma. Nature 7339:467–472
Stephens PJ, McBride DJ, Lin ML et al (2009) Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 7276:1005–1010
Pleasance ED, Cheetham RK, Stephens PJ et al (2010) A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 7278:191–196
Campbell PJ, Yachida S, Mudie LJ et al (2010) The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 7319:1109–1113
Totoki Y, Tatsuno K, Yamamoto S et al (2011) High-resolution characterization of a hepatocellular carcinoma genome. Nat Genet 5:464–469
Parsons DW, Li M, Zhang X et al (2011) The genetic landscape of the childhood cancer medulloblastoma. Science 6016:435–439
Berger MF, Lawrence MS, Demichelis F et al (2011) The genomic complexity of primary human prostate cancer. Nature 7333:214–220
Welch JS, Westervelt P, Ding L et al (2011) Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. JAMA 15:1577–1584
Wu G, Broniscer A, McEachron TA et al (2012) Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 3:251–253
Network CGAR (2011) Integrated genomic analyses of ovarian carcinoma. Nature 7353:609–615
Puente XS, Pinyol M, Quesada V et al (2011) Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 7354:101–105
Quesada V, Conde L, Villamor N et al (2012) Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 1:47–52
Wang L, Lawrence MS, Wan Y et al (2011) SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 26:2497–2506
Fabbri G, Rasi S, Rossi D et al (2011) Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med 7:1389–1401
Rozman C, Montserrat E (1995) Chronic lymphocytic leukemia. N Engl J Med 16:1052–1057
Zenz T, Mertens D, Kuppers R et al (2010) From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 1:37–50
Hamblin TJ, Davis Z, Gardiner A et al (1999) Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 6:1848–1854
Kan Z, Jaiswal BS, Stinson J et al (2010) Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 7308:869–873
Grabher C, von Boehmer H, Look AT (2006) Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nat Rev Cancer 5:347–359
Weng AP, Ferrando AA, Lee W et al (2004) Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 5694:269–271
Palomero T, Lim WK, Odom DT et al (2006) NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci USA 48:18261–18266
Tsimberidou AM, Keating MJ (2006) Richter’s transformation in chronic lymphocytic leukemia. Semin Oncol 2:250–256
Kanai M, Hanashiro K, Kim SH et al (2007) Inhibition of Crm1-p53 interaction and nuclear export of p53 by poly(ADP-ribosyl)ation. Nat Cell Biol 10:1175–1183
Wang W, Budhu A, Forgues M et al (2005) Temporal and spatial control of nucleophosmin by the Ran–Crm1 complex in centrosome duplication. Nat Cell Biol 8:823–830
Ranganathan P, Yu X, Na C et al (2012) Pre-clinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood. doi:10.1182/blood-2012-04-423160
O’Neill LA, Bowie AG (2007) The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 5:353–364
Ngo VN, Young RM, Schmitz R et al (2011) Oncogenically active MYD88 mutations in human lymphoma. Nature 7332:115–119
Kroll J, Shi X, Caprioli A et al (2005) The BTB-kelch protein KLHL6 is involved in B-lymphocyte antigen receptor signaling and germinal center formation. Mol Cell Biol 19:8531–8540
Dohner H, Stilgenbauer S, Benner A et al (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 26:1910–1916
Klein U, Lia M, Crespo M et al (2010) The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 1:28–40
Calin GA, Dumitru CD, Shimizu M et al (2002) Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 24:15524–15529
Golas MM, Sander B, Will CL et al (2003) Molecular architecture of the multiprotein splicing factor SF3b. Science 5621:980–984
Wu L, Multani AS, He H et al (2006) Pot1 deficiency initiates DNA damage checkpoint activation and aberrant homologous recombination at telomeres. Cell 1:49–62
Hockemeyer D, Daniels JP, Takai H et al (2006) Recent expansion of the telomeric complex in rodents: two distinct POT1 proteins protect mouse telomeres. Cell 1:63–77
Nagarajan P, Onami TM, Rajagopalan S et al (2009) Role of chromodomain helicase DNA-binding protein 2 in DNA damage response signaling and tumorigenesis. Oncogene 8:1053–1062
Prazeres H, Torres J, Rodrigues F et al (2011) Chromosomal, epigenetic and microRNA-mediated inactivation of LRP1B, a modulator of the extracellular environment of thyroid cancer cells. Oncogene 11:1302–1317
Quesada V, Ramsay AJ, Lopez-Otin C (2012) Chronic lymphocytic leukemia with SF3B1 mutation. N Engl J Med 26:2530
Rossi D, Bruscaggin A, Spina V et al (2011) Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood 26:6904–6908
Yoshida K, Sanada M, Shiraishi Y et al (2011) Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 7367:64–69
Graubert TA, Shen D, Ding L et al (2012) Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet 1:53–57
Papaemmanuil E, Cazzola M, Boultwood J et al (2011) Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 15:1384–1395
David CJ, Manley JL (2010) Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev 21:2343–2364
Folco EG, Coil KE, Reed R (2011) The anti-tumor drug E7107 reveals an essential role for SF3b in remodeling U2 snRNP to expose the branch point-binding region. Genes Dev 5:440–444
Corrionero A, Minana B, Valcarcel J (2011) Reduced fidelity of branch point recognition and alternative splicing induced by the anti-tumor drug spliceostatin A. Genes Dev 5:445–459
Chen AA, Marsit CJ, Christensen BC et al (2009) Genetic variation in the vitamin C transporter, SLC23A2, modifies the risk of HPV16-associated head and neck cancer. Carcinogenesis 6:977–981
Bulwin GC, Heinemann T, Bugge V et al (2006) TIRC7 inhibits T cell proliferation by modulation of CTLA-4 expression. J Immunol 10:6833–6841
Yu B, Zhou X, Li B et al (2011) FOXP1 expression and its clinicopathologic significance in nodal and extranodal diffuse large B-cell lymphoma. Ann Hematol 6:701–708
Brown PJ, Ashe SL, Leich E et al (2008) Potentially oncogenic B-cell activation-induced smaller isoforms of FOXP1 are highly expressed in the activated B cell-like subtype of DLBCL. Blood 5:2816–2824
Garbelli A, Radi M, Falchi F et al (2011) Targeting the human DEAD-box polypeptide 3 (DDX3) RNA helicase as a novel strategy to inhibit viral replication. Curr Med Chem 20:3015–3027
Yedavalli VS, Neuveut C, Chi YH et al (2004) Requirement of DDX3 DEAD box RNA helicase for HIV-1 Rev-RRE export function. Cell 3:381–392
van der Maarel SM, Scholten IH, Huber I et al (1996) Cloning and characterization of DXS6673E, a candidate gene for X-linked mental retardation in Xq13.1. Hum Mol Genet 7:887–897
Xiao S, Nalabolu SR, Aster JC et al (1998) FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nat Genet 1:84–87
Grenard P, Bates MK, Aeschlimann D (2001) Evolution of transglutaminase genes: identification of a transglutaminase gene cluster on human chromosome 15q15. Structure of the gene encoding transglutaminase X and a novel gene family member, transglutaminase Z. J Biol Chem 35:33066–33078
Stratton MR (2011) Exploring the genomes of cancer cells: progress and promise. Science 6024:1553–1558
Service RF (2006) Gene sequencing. The race for the $1000 genome. Science 5767:1544–1546
Maheswaran S, Sequist LV, Nagrath S et al (2008) Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 4:366–377
Leary RJ, Kinde I, Diehl F et al (2010) Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med 20:20ra14
Acknowledgments
This work was funded by the Spanish Ministry of Economy and Competitiveness through the Instituto de Salud Carlos III (ISCIII) and Red Temática de Investigación del Cáncer (RTICC) del ISCIII. We are very grateful to all members of the Spanish CLL Genome Consortium for their continuous support and collaboration. We are also very grateful to all patients with CLL who have participated in this study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ramsay, A.J., Martínez-Trillos, A., Jares, P. et al. Next-generation sequencing reveals the secrets of the chronic lymphocytic leukemia genome. Clin Transl Oncol 15, 3–8 (2013). https://doi.org/10.1007/s12094-012-0922-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-012-0922-z